- Lobbying
- Lobbying by Sucampo Pharmaceuticals
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Jonathan Yarowsky | GCHouse Jud. Com. 82-95; SAC Pres 95-98 |
Kirsten Donaldson | LD/GC Rep. Jeffries (13-16); Leg. Fellow House Jud. Com. (09-10) |
Timothy Martin | GC/Senior LA Rep. Tipton (14-15); LD Rep. Davis (15-17) |
Robert Lehman | CoS Portman 11-15; CoS OMB 06-07; CoS USTR 05- 06; CoS Rep Portman 03-05; CoS Rep Combest 93- 03; LD/LA Rep Combest; Lobby Spec. House Clerk 88-89 |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q3 Report
Q2 Report
Q1 Report
Q4 Report
Q3 Report
Q2 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Executive Office of the President (EOP)
Type of Issue
Registration
Issue(s) they said they’d lobby about: Issues relating to orphan drugs.
Q1 Report
Lobbying Issues
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Registration
Issue(s) they said they’d lobby about: Issues relating to orphan drugs.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate